Indaptus Therapeutics is trading $3.34 (+6.37%) after continued investor response to its September 10 announcement of a private placement raising approximately $24 million.
- Financing includes 20,338,974 shares
- Proceeds support working capital, research and development, and general corporate purposes, including potential sleep-related neurotechnology research
- Shares have advanced each session since September 3, rising from $1.16 to $3.34